# 總部位於勒克瑙的體外診斷（IVD）及醫療解決方案公司 Q-Line Biotech 宣布其 2.1448 億盧比首次公開募股。

*biotech · news · 2026-05-20 · Deccan Chronicle*

## Key points

- Q-Line Biotech 將在 NSE Emerge 平台發起 2.1448 億盧比的首次公開募股。
- Q-Line Biotech 中小企業首次公開募股將於 2026 年 5 月 21 日開啟，並於 2026 年 5 月 25 日結束。
- 募股所得將用於資金周轉 1.1 億盧比及償還 0.9 億盧比借款。
- 印度體外診斷市場預計到 2030 年將達到 29.78 億美元，年複合成長率為 12%。

Mumbai: Q-Line Biotech, a Lucknow-based in-vitro diagnostics (IVD) and healthcare solutions company, has announced its Rs 214.48 crore Initial Public Offering (IPO). The company’s shares will be listed on the NSE Emerge platform. The SME IPO will open on May 21, 2026, with a price band of Rs 326 to Rs 343 per equity share of face value Rs 10 each. The public issue will close on May 25, 2026. The net proceeds from the IPO will be used to meet working capital requirements of Rs 110 crore, repay certain borrowings worth Rs 90 crore, and for general corporate purposes. Q-Line Biotech is engaged in the manufacturing and supply of diagnostic reagents, rapid test kits, molecular diagnostics, pathology equipment, and related consumables used by hospitals and healthcare institutions. The IVD market has witnessed significant shifts in recent years, mainly due to the COVID-19 pandemic. The market grew from USD 1,237 million in CY19 to USD 2,142 million in CY21, driven by increased testing demand during the pandemic. However, the sector saw a sharp decline in CY22 and CY23 due to reduced COVID-related testing and the high base effect. With growing healthcare awareness and the rising prevalence of chronic diseases, the market started recovering in CY24 and is projected to grow at a CAGR of up to 12 per cent, reaching USD 2,978 million by 2030.

**Companies:** Q-Line Biotech
**Countries:** India

[Read the full story on Deccan Chronicle](https://www.deccanchronicle.com/business/q-line-biotech-announces-rs-21448-crore-sme-ipo-1957909)

---

Canonical: https://newsio.io/zh-TW/n/cd46cf16-ff09-4564-b614-8ce9ffb40082/ivd-q-line-biotech-2-1448-nse-emerge
Summarized by Newsio from Deccan Chronicle. https://newsio.io/how-it-works